Biotecnol Competitors and Similar CompaniesClear all
Biotecnol's competitors and similar companies include Syndax Pharmaceuticals, PDL BioPharma, PDS Biotechnology and Ascentage Pharma.
 Syndax Pharmaceuticals Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy. |  PDL BioPharma PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities. |  PDS Biotechnology PDS Biotechnology is a biopharmaceutical company focused on the development and commercialization of therapies based on the versamune platform. |  Ascentage Pharma Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies. | ||
Founding Date | Founding Date 2014 | Founding Date 2005 | Founding Date 1986 | Founding Date 2005 | Founding Date 2017 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations London, GB HQ | Locations Waltham, US HQ New York, US Waltham, US | Locations Incline Village, US HQ | Locations Princeton, US HQ Florham Park, US | Locations Suzhou, CN HQ Guangzhou Shi, CN Suzhou Shi, CN Taizhou, CN Rockville, US |
Employees | Employees 13 | Employees 358% decrease | Employees 10521% increase | Employees 317% increase | Employees 567 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.6 b | Valuation ($) 282.1 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $172.4m (FY, 2025) | Revenue (est.) $54.8m (FY, 2019) | Revenue (est.) N/A | Revenue (est.) ¥574.1m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $53.6m (FY, 2019) | Cost of goods N/A | Cost of goods ¥48.9m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $1.1m (FY, 2019) | Gross profit N/A | Gross profit ¥546.6m (FY, 2025) |
Net income | Net income N/A | Net income ($285.4m) (FY, 2025) | Net income ($70.7m) (FY, 2019) | Net income ($34.5m) (FY, 2025) | Net income (¥1.2b) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 2m | Total funding raised $ 237.5m |
For sources of this data, please see the company profile
View Company Profiles
Syndax Pharmaceuticals
HQ
Waltham, US
Employees
35↓ 8% decrease
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
View companyPDL BioPharma
HQ
Incline Village, US
Employees
105↑ 21% increase
PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities.
View companyPDS Biotechnology
HQ
Princeton, US
Employees
31↑ 7% increase
PDS Biotechnology is a biopharmaceutical company focused on the development and commercialization of therapies based on the versamune platform.
View companyAscentage Pharma
HQ
Suzhou, CN
Employees
567
Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies.
View company